Caesalpinbondin A, a Novel Diterpenoid Lactone With an Unprecedented Carbon Skeleton from the Seeds of Caesalpinia bonduc

Dong-Qing Fei1*, Hui-Hong Li1,2, Xiao-Han Chen1, Wen-Bo Cui1, Zong-Ping Zhang1, Xiao-Qing Zhan1, Mei-Jie Wang1, Feng-Ming Qi1, Zhan-Xin Zhang1* and Er-Wei Li3,4*

1School of Pharmacy, State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, China, 2Translational Medicine Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China, 3Institutional Center for Shared Technologies and Facilities, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China, 4State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

One novel diterpenoid lactone named caesalpinbondin A (1) that possesses an unprecedented tetracyclic ring system in which a 6/6/5-fused tricyclic ring and a 4,5-dimethyldihydrofuran-2(3H)-one were connected by a C-C single bond comprising a 5-(naphtho [2,3-b]furan-7-yl)dihydrofuran-2(3H)-one moiety was isolated from the seeds of Caesalpinia bonduc. Its chemical structure was established by extensive spectroscopic methods, and its absolute configuration was further determined by single-crystal X-ray diffraction analysis and electronic circular dichroism calculation. The biological evaluation suggested that compound 1 demonstrated potent anti-Alzheimer’s disease (AD) bioactivity, which could delay paralysis of transgenic AD Caenorhabditis elegans. A possible biogenetic pathway of 1 was also proposed.

Keywords: Fabaceae, Caesalpinia bonduc, diterpenoid, caesalpinbondin A, Caenorhabditis elegans, anti-Alzheimer’s disease bioactivity

INTRODUCTION

Between 1981 and 2019, approximately 50% of 1,881 new drugs approved worldwide were produced using or inspired by natural products or derivatives (Newman and Cragg, 2020). In particular, natural products, which are derived from medicinal plants with new types of architectures and amazing bioactivities, have been a rich source of drug leads and candidates.

The genus Caesalpinia, belonging to the Fabaceae family, comprises approximately 100 different kinds of plants that are mainly distributed in tropical and subtropical regions including China, Thailand, Vietnam, and other countries (Qiao et al., 2016). There are 17 Caesalpinia species in China, most of which are found in the southern regions (Wei et al., 2016). Many plants of the Caesalpinia genus have been used as a traditional medicine to treat multiple diseases in many countries all over the world (Wu et al., 2011). The chemical constituents from this genus have been reported to be terpenoids, flavonoids, steroids, lignans, phenylpropanoids, and alkaloids (Wu et al., 2011; Zanin et al., 2012). Among these constituents, the cassane-type diterpenoids, the main and characteristic chemical components of Caesalpinia, have been studied widely due to their bioactivities, such as anti-inflammatory, antitumor, antimarial, antiviral, antioxidant, and antimicrobial properties (Jing et al., 2019). Furthermore, some diterpenoids with novel skeletons have been found in plants of the Caesalpinia genus.
genus, such as caesalpininin A (Zhang et al., 2014), spiromesalmin (Jiang et al., 2001), tomocinol C, and spiromesalmin C (Xiao et al., 2016).

*Caesalpinia bonduc* (Linn.) Roxb. is a famous medicinal plant that grows mainly in tropical and subtropical regions of Southeast Asia (Pudhom et al., 2007). In China, it is mainly distributed in the southern areas, such as Guangxi, Hainan, and Taiwan (Editorial Committee of Flora of China, 1998). The seeds of *C. bonduc* have been used as a traditional Chinese medicine (TCM) for the treatment of a variety of diseases, including common cold, fever, dysentery, epigastric pain, abdominal pain, eye swelling and pain, and sores (Jiangsu New Medical College, 1977; Editorial Board of Chinese Materia Medica, 1999). Extracts or constituents of *C. bonduc* have been reported to possess cytotoxicity (Wu et al., 2014), antiproliferative (Yadav et al., 2009), anti-inflammatory (Liu et al., 2020), antistress (Kannur et al., 2006), antimicrobial (Simin et al., 2001; Arif et al., 2009), and anti-insecticidal effects (Essoung et al., 2020). Previous phytochemical investigations of *C. bonduc* have demonstrated the presence of cassane-type diterpenoids (Wu et al., 2014; Zhang et al., 2016; Liu et al., 2020; Cao et al., 2021), sterols (Udenigwe et al., 2007), and flavonoids (Ata et al., 2009). Among these chemical constituents, cassane-type diterpenoids were found to be the most important components and were considered to be active constituents of *C. bonduc*.

In our continuing search for structurally novel and biologically interesting natural products of Chinese medicinal plants (Fei et al., 2016; Li et al., 2017; Wu et al., 2018; Zhang et al., 2018; Yu et al., 2020; Li et al., 2022), a novel diterpenoid, caesalpinibondin A (1) (Figure 1), was isolated from the 95% ethanol extract of the seeds of *C. bonduc*. Compound 1 represented a novel tetracyclic ring system in which a 6/6/5-fused tricyclic ring and a 4,5-dimethyldihydrofuran-2(3H)-one moiety were connected by a C-C single bond comprising an unprecedented 5-(naphtho [2,3-b]furan-7-yl)dihydrofuran-2(3H)-one scaffold. We present the isolation, structure and stereochemistry elucidation, plausible biosynthetic pathway, and anti-AD activity of 1.

### RESULTS AND DISCUSSION

The 95% EtOH extract of the seeds of *C. bonduc* was partitioned by successive extraction with EtOAc and *n*-BuOH. The EtOAc-soluble fraction was separated by repeated column chromatography on silica gel and Sephadex LH-20 to afford compound 1.

Compound 1 was obtained as colorless needle-like crystals with [α]$_D^{20}$ +14.0 (c 0.10, CHCl$_3$). Its IR spectrum showed absorption bands assignable to carbonyl (1773 cm$^{-1}$) and aromatic ring (1,607 and 1,500 cm$^{-1}$) functionalities. The molecular formula of C$_{20}$H$_{20}$O$_3$, with 11 degrees of unsaturation, was deduced from HRESIMS at *m/z* 331.1310 [M + Na]$^+$ (calcd for C$_{20}$H$_{20}$O$_3$Na, 331.1305), which was supported by the NMR data (Table 1). The $^1$H NMR spectrum displayed signals of five aromatic protons at $\delta_H$ 7.60 (1H, d, $J$ = 9.6 Hz, H-6), 8.00 (1H, d, $J$ = 9.6 Hz, H-7), 8.05 (1H, s, H-11), 6.94 (1H, d, $J$ = 2.4 Hz, H-15), and 7.72 (1H, d, $J$ = 2.4 Hz, H-16); two benzylic angular methyls at $\delta_H$ 2.87 (3H, s, H-17) and 2.79 (3H, s, H-20); one secondary methyl at $\delta_H$ 1.32 (3H, d, $J$ = 7.2 Hz, H-19); and one tertiary methyl at $\delta_H$ 1.82 (3H, s, H-18).
addition, the $^1$H NMR spectrum showed resonances due to one aliphatic methine at $\delta^H$ 3.08 (1H, m, H-3) and one aliphatic methylene at $\delta^H$ 2.18 (1H, dd, $J = 18.0$, 3.0 Hz, H-2a) and 2.59 (1H, dd, $J = 18.0$, 3.0 Hz, H-2b). The $^{13}$C and DEPT NMR spectra revealed 20 resonances ascribed to four methyls, one methylene, six methines (five olefinic and one aliphatic), and nine quaternary carbons (one carbonyl, seven olefinic, and one oxygenated aliphatic). Among them, one carbonyl and twelve sp$^2$-hybridized carbons indicated seven degrees of unsaturation. These data suggested that compound 1 is a diterpenoid possessing a tetracyclic ring system in the scaffold.

The planar structure of 1 was elucidated by extensive analysis of the two-dimensional (2D) NMR experiments. The proton and proton-bearing carbon resonances in the NMR spectra of 1 were assigned unambiguously by comprehensive interpretation of the $^1$H–$^1$H COSY (Figure 2) and HSQC spectroscopic data. The proton spin–spin coupling system from H-6 to H-7 in the $^1$H–$^1$H COSY spectrum, in combination with the HMBC correlations (Figure 2) from H$_3$-20 to C-5, C-9, and C-10, from H-6 to C-5, C-7, C-8, and C-10, from H-7 to C-5, C-6, C-8, and C-9, demonstrated the presence of a benzene ring A with a methyl group at C-10. Moreover, the HMBC correlations of H$_3$-17 with C-8, C-13, and C-14 and of H-11 with C-8, C-9, C-10, C-12, and C-13 indicated the existence of a benzene ring B fused with ring A through the positions between C-8 and C-9 with a methyl group at C-14. Subsequently, the $^1$H–$^1$H COSY correlation of H-15 with H-16, the HMBC correlations of H-15 with C-12, C-13, C-14, and C-16, and the HMBC correlations of H-16 with C-12, C-13, and C-15, in

| No. | $\delta^C$ | $\delta^H$ Mult ($J$, Hz) | HMBC |
|-----|-----------|------------------------|-------|
| 1   | 176.4, qC  | —                      | —     |
| 2   | 37.2, CH$_2$ | 2.59, dd (18.0, 3.0)  | 1, 3, 4, and 19 |
|     |           | 2.18, dd (18.0, 3.0)  | —     |
| 3   | 39.4, CH  | 3.08, m               | 1, 2, 4, 5, 18, and 19 |
| 4   | 90.4, qC  | —                      | —     |
| 5   | 138.6, qC | —                      | —     |
| 6   | 120.2, CH | 7.60, d (9.6)         | 4, 5, 7, 8, and 10 |
| 7   | 122.7, CH | 8.00, d (9.6)         | 5, 6, 8, 9, and 14 |
| 8   | 128.2, qC | —                      | —     |
| 9   | 132.3, qC | —                      | —     |
| 10  | 129.4, qC | —                      | —     |
| 11  | 101.6, CH | 8.05, s               | 8, 9, 10, 12, and 13 |
| 12  | 153.9, qC | —                      | —     |
| 13  | 127.8, qC | —                      | —     |
| 14  | 126.4, qC | —                      | —     |
| 15  | 105.2, CH | 6.94, d (2.4)         | 12, 13, 14, and 16 |
| 16  | 146.9, CH | 7.72, d (2.4)         | 12, 13, and 15 |
| 17  | 15.6, CH$_3$ | 2.87, s              | 8, 13, and 14 |
| 18  | 23.5, CH$_3$ | 1.82, s              | 3, 4, and 5 |
| 19  | 16.4, CH$_3$ | 1.32, d (72)         | 2, 3, and 4 |
| 20  | 17.9, CH$_3$ | 2.79, s              | 5, 9, and 10 |
combination with the dramatically downfield chemical shifts of C-12 ($\delta_C$ 153.9) and C-16 ($\delta_C$ 146.9), suggested the existence of a furan ring C fused with ring B through the positions between C-12 and C-13. Additionally, the $^1$H–$^1$H COSY correlations of H$_2$-2/H$_3$-3/H$_3$-19, as well as the HMBC cross-peaks of H$_2$-2 with C-1, C-3, and C-4, of H-3 with C-1, C-2, and C-4, and of H$_3$-19 with C-2, C-3, and C-4, revealed that the carbonyl C-1 of 1 ($\delta_C$ 176.4) formed a $\gamma$-butyrolactone (ring D) with the oxygenated C-4 (downfield chemical shift at $\delta_C$ 90.4) to occupy the remaining one degree of unsaturation. The HMBC correlations of H$_3$-19 with C-2, C-3, and C-4 and of H$_3$-19 with C-3 and C-4 indicated that CH$_2$-19 and CH$_3$-18 were located at C-3 and C-4, respectively. Based on the HMBC correlations of H$_3$-19 with C-5 and of H-6 with C-4, it was further apparent that the ring D and ring A were linked between C-4 and C-5 by a C-C single bond.

The relative configuration of 1 was determined by NOESY analysis. In the NOESY spectrum (Figure 3), the NOE correlation between H$_3$-18 and H$_3$-19 indicated that H$_3$-18 and H$_3$-19 were oriented on the same side of the $\gamma$-butyrolactone moiety ([$\beta$-configuration]). Thus, the planar structure and relative configuration of 1 were determined as shown in Figure 1. After many attempts to crystallize 1 using different solvents, a single crystal of 1 was finally obtained from CHCl$_3$-MeOH (2:3). The subsequent X-ray crystallographic analysis (Cu Kα) clarified the planar structure and the relative configuration of 1 (Figure 4). However, the Flack parameter (-0.3 (3)) was somewhat large, precluding assignment of the absolute configuration of 1 by this method. Thus, ECD calculation was utilized to identify the absolute configuration of 1. Using quantum-mechanical time-dependent density functional theory (TDDFT) calculation, the theoretically calculated ECD spectrum of 1 (Figure 5) was in good agreement with the experimental ECD spectrum, supporting the assignment of the absolute configuration of 1 as 3 and 4R. Thus, the structure of 1 was established and named caesalpinbondin A.

Caesalpinbondin A (1) possessed an unconventional tetracyclic diterpenoid backbone, in which a 6/6/5-fused tricyclic ring system was connected to a 4,5-dimethylidihydrofuran-2(3H)-one moiety via a C-C single bond. The aforementioned analyses proved 1 as a diterpenoid with a new carbon skeleton architecture, and the name “caesalpinane” is suggested for this new skeleton type.

A hypothetical biosynthetic route was proposed, as shown in Scheme 1. Compound 1 should be originated from geranylgeranyl pyrophosphate (GGPP), which is a typical precursor of diterpenoids. First, labdadienyl pyrophosphate (LDPP) was produced from GGPP by an acid-induced intramolecular cyclization, and then the pimarane-type diterpenoid cation intermediate was generated from LDPP through further intramolecular cyclization and converted to the cassane-type diterpenoid via the migration of methyl 17 from C-13 to C-14 (Zentar et al., 2018; Jing et al., 2019). The cassane-type diterpenoid was transformed into furan-cassane diterpenoid through oxidation,
nucleophilic ring closure, and dehydration reactions (Zhang et al., 2013). Next, compound A could be derived from the furan-cassane diterpenoid via oxidation reaction and further hydrogenated and dehydrated to afford a key carbocation intermediate C, which could be converted to D by the migration of methyl 19 from C-4 to C-3. Subsequent oxidation and addition of compound D may lead to the formation of compound E, which could go through Baeyer–Villiger oxidation to give compound F. Hydrolysis of compound F followed by dehydrated and intramolecular esterification reaction could produce compound I, which would give compound 1 by an enzyme-mediated aromatization.

Furthermore, the anti-Alzheimer’s disease (AD) bioactivity of compound 1 was evaluated using the transgenic AD Caenorhabditis elegans model with memantine as the positive control (Figure 6). The AD model (CL4176) is based on the transfer of the human Aβ1-42 gene downstream of the nematode myo-3 promoter. When incubated at a normal temperature of 15°C, the nematodes did not express Aβ1-42, and when the temperature was adjusted upward to 25°C, Aβ1-42 began to accumulate in the muscle cells and induced a toxic response that paralyzed the nematodes. If the number of nematode individuals in the paralyzed state was reduced in the administered group

![Scheme 1](image1)

![Figure 6](image2)
compared to the blank group, the compound was shown to have anti-AD activity. For its cheapness, easy and fast-breeding, and AD pathological similarity, the transgenic AD *C. elegans* model has been used as a powerful tool for rapid screening of anti-AD drugs (Xin et al., 2013). Using transgenic AD *C. elegans* paralysis assay, we have successfully discovered several natural products with potential anti-AD effects (Li et al., 2017; Wu et al., 2018; Su et al., 2021). As shown in Figure 6, compound 1 significantly delayed the Aβ-induced paralysis in CL4176 nematodes (*p* < 0.05). At 44th h of upregulated temperature induction, 33.40% of nematodes were still unparalyzed in the 100 μM compound 1-treated group, while only 22.24% of unparalyzed nematodes remained in the 0.1% DMSO-treated group. The result of the bioactivity assay indeed gave a notion that compound 1 may have the potential to be served as an anti-AD agent candidate.

CONCLUSION

In summary, our further exploration of the minor chemical constituents from *C. bonduc* yielded one new carbon skeleton diterpenoid, caesalpinibondin A (1). The novel diterpenoid 1 possessed an unprecedented 6/6/5-fused ring system with a 4,5-dimethyldihydrofuran-2(3H)-one moiety scaffold. The discovery of 1 has enriched the diversity and complexity of natural diterpenoids. In addition, compound 1 exhibited good delayed AD-like symptoms of worm paralysis phenotype activity, suggesting that this compound may be useful for the development of anti-AD drugs. These findings will attract much attention from both chemists and pharmacologists, and further research such as total synthesis and in-depth pharmacological tests are warranted.

EXPERIMENTAL SECTION

General Experimental Procedures

Melting points were measured using an X-4 digital display micromelting point apparatus (Beijing Tech Instrument Co., Ltd., Beijing, China) and are uncorrected. Optical rotations were obtained on a PerkinElmer 341 polarimeter (PerkinElmer, Waltham, MA, United States). IR spectra were run on a Nicolet NEXUS 670 FT-IR spectrometer (ThermoFisher Scientific Inc., Waltham, MA, United States). The ECD spectra were measured on an OLIS DSM1000 spectrophotometer (Olis, Inc., Bogart, GA, United States) at room temperature. The 1D and 2D NMR experiments were conducted on a Varian INOVA 600 MHz NMR spectrometer (Varian Inc. Palo Alto, CA, United States) and used TMS as the internal standard. The HRESIMS data were collected on a ThermoFisher LTQ Orbitrap Elite high-resolution mass spectrometer (Thermo Fisher Scientific Inc. Waltham, MA, United States). The X-ray crystallographic analysis was performed on an Agilent SuperNova dual-wavelength diffractometer with a microfocus X-ray source and multilayer optics monochromatized Cu Kα (λ = 1.54184 Å) radiation (Agilent Technologies, Santa Clara, CA, United States). Silica gel (200-300 mesh (Qingdao Marine Chemical Factory, Qingdao, China) and Sephadex LH-20 (GE Healthcare Amersham Biosciences, Uppsala, Sweden) for column chromatography were used to separate compounds. Silica gel GF254 (10–40 μm) used for TLC was supplied by Qingdao Marine Chemical Factory, Qingdao, China. Spots were detected on TLC under UV light or by heating after spraying with 5% H2SO4 in C2H6OH (v/v).

Plant Material

The seeds of *C. bonduc* were purchased in April 2014 from the Anguo Traditional Chinese Medicine Market in Hebei Province, China, and identified by Dr. Jian-yin Li of School of Pharmacy, Lanzhou University. A voucher specimen (No. 20140418CB) was deposited at the School of Pharmacy, Lanzhou University, China.

Extraction and Isolation

The air-dried and powdered seeds of *C. bonduc* (12 kg) were extracted with 95% EtOH (40 L × 4) at room temperature. Evaporation of the organic solvent afforded 920 g of a crude extract, which was suspended in water and successively partitioned into EtOAc and n-BuOH extracts. The EtOAc extract (300 g) was separated over a silica gel column with a petroleum ether/acetone gradient (from 40:1 to 0:1, v/v) eluent to provide seven fractions (Fr.1–Fr.7). Fraction 2 (25 g) was chromatographed over silica gel eluted with petroleum ether/EtOAc (from 30:1 to 3:1, v/v) to yield four subfractions (Fr.2A–Fr.2D). Fr.2C (900 mg) was subjected to passage over a silica gel column with petroleum ether/acetone (from 20:1 to 0:1, v/v) and then applied to Sephadex LH-20 column chromatography (CHCl3/CH3OH, 2:3, v/v) to obtain 1 (5 mg).

Physical and Chemical Data

Caesalpinibondin A (1): colorless needle-like crystals, m. p. 218–220°C [α]D20 +14.0 (c 0.10, CHCl3); IR (KBr) v max: 2,974, 2,926, 1,773, 1,638, 1,607, 1,543, 1,500, 1,459, 1,385, 1,231, 1,142, 1,045, 934, 756, and 666 cm−1; 1H (600 MHz) and 13C (150 MHz) NMR data, see Table 1; HRESIMS m/z 331.1310 [M + Na]+ (calcd. for C20H19O3Na, 331.1305).

Single Crystal X-Ray Diffraction Data Collection

Single crystals of compound 1 was obtained by recrystallization from a mixture of CHCl3 and MeOH. Crystal data for 1: C20H19O3, Mr = 308.36, orthorhombic, space group P212121, a = 6.26793 (18) Å, b = 12.7202 (4) Å, c = 20.3959 (6) Å, α = 90.00°, β = 90.00°, γ = 90.00°, V = 20.3959 (6) Å3, Z = 293 (2) K, Z = 4, d = 1.260 g/cm3, μ(Cu Kα) = 0.67 mm−1, F(000) = 656, and crystal dimensions 0.24 × 0.09 × 0.07 mm were used for measurement on an Agilent Technologies SuperNova, Dual source, EOS CCD with mirror optics, using graphite monochromated Cu Kα radiation (λ = 1.54184 Å). The total of 13,844 reflections measured 3,009 independent reflections (Rint = 0.0371). The final R1 value was 0.0428 (I > 2σ(I)). The final wR2 value was 0.1116 (I > 2σ(I)). The final R1 value was 0.0610 (all data). The final wR2 (F2) value was 0.0972 (all data). The goodness of fit on F2 was 1.031. The Flack parameter was -0.3 (3). Crystallographic data for the structure of compound 1 have been deposited with the Cambridge Crystallographic Data Centre (deposition no. CCDC 2106390). Copies of these data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12
were compared with the experimental results for the absolute negative control for the entire biological activity determination of the other inferior. The anti-AD activity was determined by using a compound with a higher anti-AD activity located on the topside of others. It can be identified that the non-paralysis curve of a compound with a higher anti-AD activity locates on the topside of the other inferior. The anti-AD activity was determined by using log-rank survival test to compare the significance between treatments (Martorell et al., 2013). The p-value at a level of 0.05 or less was considered to be statistically significant.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are publicly available. These data can be found at: https://www.ccdc.cam.ac.uk/, 2106390.

**AUTHOR CONTRIBUTIONS**

D-QF, Z-XZ, and E-WL contributed to the conception and design of the research. H-HL, X-HC, X-QZ, and M-JW undertook the isolation, purification, and identification work. W-BC and Z-PZ performed the activity testing work. F-MQ carried out the 1D and 2D-NMR spectra data. D-QF, Z-XZ, and E-WL undertook the writing work of the manuscript. All authors contributed to the article and approved the submitted manuscript version.

**FUNDING**

This research was financially supported by the National Natural Science Foundation of China (Grant Nos. 31670350 and 31870324) and the Natural Science Foundation of Gansu Province, China (Grant Nos. 21JR7RA444 and 21JR7RA477).

**ACKNOWLEDGMENTS**

We thank Professor Shao-hua Wang of the School of Pharmacy, Lanzhou University, for his valuable suggestions on the proposed biosynthetic pathway. We also acknowledge Yong-liang Shao of State Key Laboratory of Applied Organic Chemistry, Lanzhou University, for his professional measurements of the X-ray diffraction.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2022.911543/full#supplementary-material

---

**ECD Calculations**

The conformational search for the enantiomers of all plausible stereoisomers of 1 was performed by the “random search” procedure implemented in the SYBYL-X-2.1.1 program using the Molecular Merck force field (MMFF94s). Gaussian 09 software was applied to screen stable conformers with the energy of the optimized structures at the B3LYP/6-31G(d) level (Frisch et al., 2010). The ECD curves of the conformers were determined by the TDDFT method at the B3LYP/6-31+G(d) level with the CPCM model in a methanol solution. SpecDis 1.7.1 software with UV correction was used to weigh the overall ECD curves by the Boltzmann distribution of each conformer (Bruhn et al., 2017). The calculated ECD curves of 1 were compared with the experimental results for the absolute configuration determination.

**Bioactivity Assay for Alzheimer’s Disease-Like Phenotype of Delaying PARALYSIS in Caenorhabditis elegans**

The genetically modified Caenorhabditis elegans CL4176 strain with genotype smg-1 [myo-3p: A-Beta (1–42); let-851 3’UTR] + rol-6 (su1006)] was purchased from the Caenorhabditis Genetics Center (CGC) (University of Minnesota, Minneapolis, MN). Using Escherichia coli OP50 as the standard food source, worms were cultured on nematode growth medium (NGM) at 16°C. A total of 60–80 eggs were placed in NGM, and 0.1% DMSO was used as a negative control for the entire biological activity determination experiment. After the larvae developed into L3 larvae, they were transferred to another 25°C incubator and incubated for 26 h. The paralyzed worms were observed and counted under a dissecting microscope every 2 h until they were all paralyzed. The non-paralysis curve was plotted by incubation time at 25°C as x-axis and non-paralytic worm percentage as y-axis throughout the experiment. The compound delaying the rate of worm paralysis more effectively means that it has higher anti-AD activity than any others. It can be identified that the non-paralysis curve of a compound with a higher anti-AD activity locates on the topside of the other inferior. The anti-AD activity was determined by using a log-rank survival test to compare the significance between treatments (Martorell et al., 2013). The p-value at a level of 0.05 or less was considered to be statistically significant.

**REFERENCES**

Arif, T., Mandal, T. K., Kumar, N., Bhosale, J. D., Hole, A., Sharma, G. L., et al. (2009). In Vitro and In Vivo Antimicrobial Activities of Seeds of Caesalpinia bonduc L (Lin.) Roxb. J. Ethnopharmacol. 123, 177–180. doi:10.1016/j.jep.2009.02.040

Ata, A., Gale, E. M., and Samarasekera, R. (2009). Bioactive Chemical Constituents of Caesalpinia Bondac (Fabaceae). Phytochem. Lett. 2, 106–109. doi:10.1016/j.phytol.2009.02.002

Bruhn, T., Schaumlöffel, A., Hemberger, Y., and Pecitelli, G. (2017). SpecDis Version 1.7.1. Berlin, Germany.

Cao, J., Xu, Y. S., Lou, R. H., Shi, W., Chen, J. L., Gan, L. S., et al. (2021). Cassane-Type Diterpenoids from the Seeds of Caesalpinia bondac (L.) Roxb. Chem. Biodivers. 18, e2100309. doi:10.1002/cbdv.202100309

---

**FUNDING**

Editorial Board of Chinese Materia Medica (1999). Chinese Materia Medica, 11. Shanghai: Shanghai Science and Technology Press, 368–369.

Editorial Committee of Flora of China (1998). "Chinese Academy of Sciences," in Flora of China. Beijing: Science Press, 42, 366.

Essoung, F. R. E., Mba ‘ning, B. M., Tcho, A. T., Chhabra, S. C., Mohamed, S. A., Lenta, B. N., et al. (2020). Antifeedant and Ovicidal Activities of A New Cassane and Other Compounds from Caesalpinia Welwitschiana Oliv. And Caesalpinia Bondac L. Against Tuta Absoluta (Lepidoptera: Gelechiidae). Nat. Prod. Res. 35, 5681–5691. doi:10.1080/14786419.2020.1825424

Fei, D. Q., Dong, L. L., Qi, F. M., Fan, G. X., Li, H. H., Li, Z. Y., et al. (2016). Fei, D. Q., Dong, L. L., Qi, F. M., Fan, G. X., Li, H. H., Li, Z. Y., et al. (2016). Euphorikanin A, A Diterpenoid Lactone with A Fused 5/6/7/3 Ring System from Euphorbia kansui. J. Ethnopharmacol. 123, 177–180. doi:10.1016/j.jep.2009.02.040

Fei, D. Q., Dong, L. L., Qi, F. M., Fan, G. X., Li, H. H., Li, Z. Y., et al. (2016). Euphorikanin A, A Diterpenoid Lactone with A Fused 5/6/7/3 Ring System from Euphorbia kansui. J. Ethnopharmacol. 123, 177–180. doi:10.1016/j.jep.2009.02.040

Essoung, F. R. E., Mba ‘ning, B. M., Tcho, A. T., Chhabra, S. C., Mohamed, S. A., Lenta, B. N., et al. (2020). Antifeedant and Ovicidal Activities of A New Cassane and Other Compounds from Caesalpinia Welwitschiana Oliv. And Caesalpinia Bondac L. Against Tuta Absoluta (Lepidoptera: Gelechiidae). Nat. Prod. Res. 35, 5681–5691. doi:10.1080/14786419.2020.1825424

Fei, D. Q., Dong, L. L., Qi, F. M., Fan, G. X., Li, H. H., Li, Z. Y., et al. (2016). Euphorikanin A, A Diterpenoid Lactone with A Fused 5/6/7/3 Ring System from Euphorbia kansui. J. Ethnopharmacol. 123, 177–180. doi:10.1016/j.jep.2009.02.040
Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., et al. (2010). Gaussian 09, Revision C01. Wallingford, CT: Gaussian, Inc.

Jiang, R. W., Ma, S. C., But, P. P. H., and Mak, T. C. W. (2001). Isolation and Characterization of Spirocaesarins, A Novel Spiral-Activated Diterpenoid from Caesalpinia Minax Hance. J. Chem. Soc., Perkin Trans. 1, 22, 2920–2923. doi:10.1039/b10743n

Jiangsu New Medical College (1977). Dictionary of Chinese Traditional Medicine. Shanghai: Shanghai People’s Publishing House, 1289.

Jing, W. H., Zhang, X. X., Zhou, H. X., Wang, Y., Yang, M. Q., Long, L. P., et al. (2019). Naturally Occurring Cassane Diterpenoids (CDs) of Cassaerin: A Systematic Review of its Biosynthesis, Chemistry and Pharmacology. Fitoterapia 134, 226–249. doi:10.1016/j.fitote.2019.02.023

Kannur, D. M., Hukkeri, V., and Akki, K. S. (2006). Adaptogenic Activity of Cassane Diterpenoid from the Seeds of Caesalpinia Minax Sappan. Chin. Chem. Lett. 27, 1751–1754. doi:10.1016/j.cclet.2016.04.022

Xin, L. J., Yamujala, R., Wang, Y. H., Wang, H., Wu, W. H., Lawton, M. A., et al. (2013). Acetylcholineesterase-Inhibiting Alkaloids from Lycoris Radiata Delay Paralysis of Amyloid Beta-Expressing Transgenic C. elegans CL4176. PLoS One 8, e63874. doi:10.1371/journal.pone.0063874

Yadav, P. P., Maurya, R., Sarkar, J., Arora, A., Kanojiya, S., Sinha, S., et al. (2009). Cassane Diterpenes from Caesalpinia Bonduc. Phytochemistry 70, 256–261. doi:10.1016/j.phytochem.2008.12.008

Yu, C. X., Wang, R. Y., Qi, F. M., Su, P. J., Yu, Y. F., Li, B., et al. (2020). Eupulcherol A, A Triterpenoid with A New Carbon Skeleton from Euphorbia pulcherrima, and its Anti-alzheimer’s Disease Bioactivity. Org. Biomol. Chem. 18, 76–80. doi:10.1039/c9ob02334h

Zannin, J. L. B., De Carvalho, A. B., Salles Martinelli, P., Dos Santos, M. H., Lago, J. H. G., Sartorelli, P., et al. (2012). The Genus Cassaerin (Caesalpininae): Phytochemical and Pharmacological Characteristics. Molecules 17, 7887–7902. doi:10.3390/molecules17077887

Zeng, H., Arias, F., Hadzou, A., Alvarez-Manzaneda, R., Chahboun, R., and Alvarez-Manzaneda, E. (2018). Protecting-Group-Free Synthesis of Cassane-type Furan Diterpenes via A Decarboxylative Dienone-Phenol Rearrangement. Org. Lett. 20, 7007–7010. doi:10.1021/acs.lett.8b02867

Zhang, J. L., Tian, H. Y., Chen, N. H., Bai, X. Y., Li, J., Zhang, R. R., et al. (2014). Cassaeriniminin A, A Novel Rearranged Furanditerpenone with an Unprecedented Carbon Skeleton from the Seeds of Caesalpinia Minax Hance. RSC Adv. 4, 7440–7443. doi:10.1039/c4ra46502k

Zhang, J. Y., Abdel-Mageed, W. M., Liu, M. M., Huang, P., He, W. N., Li, L., et al. (2013). Cassaines A-D New Cassane Diterpenes with Unprecedented N Bridge from Caesalpinia Sappan. J. Nat. Prod. 15, 4726–4729. doi:10.1021/acs.jnatprod.3005280

Zhang, P. P., Tang, C. P., Yao, S., Ke, C. Q., Lin, G., Hua, H. M., et al. (2016). Cassane Diterpenoids from the Pericarps of Caesalpinia Bonduc. J. Nat. Prod. 79, 24–29. doi:10.1021/acs.jnatprod.5b00520

Zhang, X. Z., Wu, P. Q., Li, H. H., Qi, F. M., Fei, D. Q., Hu, Q. L., et al. (2018). Norcrassin A, A Novel C16 Tetranor-diterpenoid, and Bicotonol A, an Unusual Dimeric Labdane-type Diterpenoid, from the Roots of Croton Crassifolius. Org. Biomol. Chem. 16, 1745–1750. doi:10.1039/c7ob02991h

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fei, Li, Chen, Cui, Zhang, Zhan, Wang, Qi, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.